Results 21 to 30 of about 4,367 (184)
Gastro Hep AdvancesBackground and Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in patients with Crohn’s ...
Brian G. Feagan +13 more
doaj +2 more sources
Esophageal Crohn's Disease Successfully Treated With Risankizumab. [PDF]
ACG Case Rep JEsophageal Crohn\u2019s disease (CD) is poorly studied despite being a significant predictor of intestinal CD progression and recurrence. Management has historically focused on steroids and acid suppression, with some success from immunosuppressants and ...
Hallcox T, Stein D.
europepmc +2 more sources
, 2023 Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar ...
Gaia Moretta +9 more
core +1 more source
Risankizumab: Daily Practice Experience of High Need Patients [PDF]
, 2023 Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions ...
Caldarola G.
core +2 more sources
Frontiers in Immunology, 2023 BackgroundRisankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease.
Yamin Shu +3 more
doaj +1 more source
Risankizumab in the treatment of psoriasis – literature review
Rheumatology, 2019 Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis.
Katarzyna Banaszczyk
doaj +1 more source
A non-clinical comparative study of IL-23 antibodies in psoriasis
mAbs, 2021 Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou +19 more
doaj +1 more source
Peristomal Pyoderma Gangrenosum Responding to Risankizumab
, 2021 Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve
Kirsner, Robert S +1 more
core +1 more source
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil [PDF]
Anais Brasileiros de Dermatologia: Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective: The authors
Tania F. Cestari +16 more
doaj +1 more source
, 2023 Background and Aims Durable clinical remission, endoscopic healing, and biomarker normalization are key treatment goals for Crohn’s disease. The selective anti-interleukin-23 p19 inhibitor risankizumab demonstrated efficacy and safety in moderately to ...
Alexandra Song +39 more
core +1 more source